XBiotech Inc. (XBIT)
NASDAQ: XBIT · Real-Time Price · USD
7.30
-0.05 (-0.68%)
Nov 4, 2024, 4:00 PM EST - Market closed
XBiotech Employees
XBiotech had 82 employees as of December 31, 2023. The number of employees decreased by 3 or -3.53% compared to the previous year.
Employees
82
Change (1Y)
-3
Growth (1Y)
-3.53%
Revenue / Employee
n/a
Profits / Employee
-$426,915
Market Cap
222.38M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
2seventy bio | 274 |
Utah Medical Products | 190 |
Inhibrx Biosciences | 172 |
Molecular Partners AG | 168 |
Nkarta | 150 |
Nektar Therapeutics | 137 |
Mersana Therapeutics | 123 |
Solid Biosciences | 88 |
XBIT News
- 4 months ago - What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? - Benzinga
- 4 months ago - XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer - GlobeNewsWire
- 5 months ago - XBiotech: Several Shots On Goal In Big Target Market Indications - Seeking Alpha
- 10 months ago - XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus - GlobeNewsWire
- 1 year ago - Dr. Alan Kivitz to Chair XBiotech's Natrunix Program in Rheumatoid Arthritis - GlobeNewsWire
- 1 year ago - XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke - GlobeNewsWire
- 1 year ago - XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer - GlobeNewsWire
- 1 year ago - XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial - GlobeNewsWire